Suppr超能文献

胸腺瘤来源的胸上皮细胞中 mTOR/Akt 通路的激活。

Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas.

机构信息

IVPC UMR754 INRA, Univ Lyon, Université Claude Bernard Lyon 1, EPHE, Lyon, France.

Department of Thoracic Surgery, Lung and Heart-lung Transplantation, Groupement Hospitalier Est, HCL, Lyon, France.

出版信息

PLoS One. 2019 Mar 21;14(3):e0197655. doi: 10.1371/journal.pone.0197655. eCollection 2019.

Abstract

The pathogenesis of thymic epithelial tumors remains poorly elucidated. The PIK3/Akt/mTOR pathway plays a key role in various cancers; interestingly, several phase I/II studies have reported a positive effect of mTOR inhibitors in disease control in thymoma patients. A major limit for deciphering cellular and molecular events leading to the transformation of thymic epithelial cells or for testing drug candidates is the lack of reliable in vitro cell system. We analyzed protein expression and activation of key players of the Akt/ mTOR pathway namely Akt, mTOR, and P70S6K in eleven A, B and AB thymomas as well as in normal thymuses. While only Akt and phospho-Akt were expressed in normal thymuses, both Akt and mTOR were activated in thymomas. Phospho-P70S6K was expressed in all thymic tumors whatever their subtypes, and absent in normal thymus. Interestingly, we report the activation of Akt, mTOR and P70S6 proteins in primary thymic epithelial cells maintained for short period of time after their derivation from seven AB and B thymomas. Finally, we showed that rapamycin (100 nM) significantly reduced proliferation of thymoma- derived epithelial cells without inducing cell death. Our results suggest that the activation of the Akt/ mTOR pathway might participate to the cell proliferation associated with tumor growth. Ultimately, our data enhance the potential role of thymic epithelial cells derived from tissue specimens for in vitro exploration of molecular abnormalities in rare thymic tumors.

摘要

胸腺瘤的发病机制仍不清楚。PI3K/Akt/mTOR 途径在各种癌症中起着关键作用;有趣的是,几项 I/II 期研究报告称,mTOR 抑制剂可控制胸腺瘤患者的疾病。解析导致胸腺上皮细胞转化的细胞和分子事件或测试候选药物的主要限制是缺乏可靠的体外细胞系统。我们分析了 Akt/mTOR 途径的关键分子,即 Akt、mTOR 和 P70S6K 在 11 例 A、B 和 AB 胸腺瘤以及正常胸腺中的蛋白表达和激活情况。虽然正常胸腺中仅表达 Akt 和磷酸化 Akt,但胸腺瘤中均激活了 Akt 和 mTOR。磷酸化 P70S6K 在所有胸腺瘤中表达,无论其亚型如何,在正常胸腺中均不存在。有趣的是,我们报告了在从 7 例 AB 和 B 胸腺瘤中分离出的短时间内维持的原发性胸腺瘤上皮细胞中 Akt、mTOR 和 P70S6 蛋白的激活。最后,我们表明雷帕霉素(100 nM)可显著抑制胸腺瘤衍生的上皮细胞的增殖,而不会诱导细胞死亡。我们的结果表明,Akt/mTOR 途径的激活可能参与与肿瘤生长相关的细胞增殖。最终,我们的数据增强了源自组织标本的胸腺上皮细胞在体外探索罕见胸腺瘤中分子异常的潜在作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1b3/6428316/309c5efe5b56/pone.0197655.g001.jpg

相似文献

1
Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas.
PLoS One. 2019 Mar 21;14(3):e0197655. doi: 10.1371/journal.pone.0197655. eCollection 2019.
2
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Lung Cancer. 2017 Feb;104:24-30. doi: 10.1016/j.lungcan.2016.12.005. Epub 2016 Dec 14.
3
The Akt/mTOR/p70S6K pathway is activated in IgA nephropathy and rapamycin may represent a viable treatment option.
Exp Mol Pathol. 2015 Dec;99(3):435-40. doi: 10.1016/j.yexmp.2015.08.004. Epub 2015 Aug 19.
4
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9. doi: 10.1167/iovs.09-3974. Epub 2009 Aug 6.
5
Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms.
Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):210-5. doi: 10.1097/00129039-200009000-00007.
7
A Knock-In Mouse Model of Thymoma With the GTF2I L424H Mutation.
J Thorac Oncol. 2022 Dec;17(12):1375-1386. doi: 10.1016/j.jtho.2022.08.008. Epub 2022 Aug 30.
8
Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Br J Dermatol. 2009 Aug;161(2):357-63. doi: 10.1111/j.1365-2133.2009.09179.x. Epub 2009 Apr 29.

引用本文的文献

1
The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive Review.
Int J Mol Sci. 2024 Jan 26;25(3):1554. doi: 10.3390/ijms25031554.
3
Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures.
Front Immunol. 2023 Oct 2;14:1264325. doi: 10.3389/fimmu.2023.1264325. eCollection 2023.
4
Emerging therapies in thymic epithelial tumors (Review).
Oncol Lett. 2023 Jan 16;25(2):84. doi: 10.3892/ol.2023.13670. eCollection 2023 Feb.
5
A phase II study of buparlisib in relapsed or refractory thymomas.
Front Oncol. 2022 Oct 18;12:891383. doi: 10.3389/fonc.2022.891383. eCollection 2022.
7
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?
Cancers (Basel). 2022 Feb 2;14(3):774. doi: 10.3390/cancers14030774.
9
Thymic tumours and their special features.
Eur Respir Rev. 2021 Oct 20;30(162). doi: 10.1183/16000617.0394-2020. Print 2021 Dec 31.
10
An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances.
Pharmaceuticals (Basel). 2021 Apr 1;14(4):316. doi: 10.3390/ph14040316.

本文引用的文献

1
The Integrated Genomic Landscape of Thymic Epithelial Tumors.
Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.
2
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
J Clin Oncol. 2018 Feb 1;36(4):342-349. doi: 10.1200/JCO.2017.74.4078. Epub 2017 Dec 14.
3
mTORC1 and mTORC2 in cancer and the tumor microenvironment.
Oncogene. 2017 Apr 20;36(16):2191-2201. doi: 10.1038/onc.2016.363. Epub 2016 Oct 17.
5
Crizotinib resistance: implications for therapeutic strategies.
Ann Oncol. 2016 Sep;27 Suppl 3(Suppl 3):iii42-iii50. doi: 10.1093/annonc/mdw305.
7
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.
J Thorac Oncol. 2016 Aug;11(8):1345-1356. doi: 10.1016/j.jtho.2016.04.013. Epub 2016 Apr 24.
8
Thymoma and thymic carcinomas.
Crit Rev Oncol Hematol. 2016 Mar;99:332-50. doi: 10.1016/j.critrevonc.2016.01.012. Epub 2016 Jan 19.
9
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.
Br J Cancer. 2016 Feb 16;114(4):477-84. doi: 10.1038/bjc.2015.425. Epub 2016 Jan 14.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验